AgroSpectrum ASIA
Envisaging Future | Updating Present

Traitomic raises â?¬20 million to accelerate non-GM crop trait development

19 November 2026 | News

The Carlsberg spinout will use its Series A funding to expand internationally and strengthen its FIND-IT platform for developing improved traits in crops and microorganisms without gene editing.



Copenhagen-based biotechnology company Traitomic has raised €20 million in a Series A funding round led by Sofinnova Partners to accelerate the development and commercialisation of plant and microbial traits without genetic engineering. The investment will support international expansion, scientific research and broader trait development services for customers across agriculture, food production and industrial biotechnology.

The funding round also attracted participation from the Export and Investment Fund of Denmark (EIFO), Footprint Firm, Nordic Foodtech VC, PSV Hafnium and SVG Ventures. It represents Traitomic's first external investment since becoming an independent company following its spinout from Carlsberg.

FIND-IT technology supports conventional trait development

Traitomic uses its proprietary FIND-IT platform to identify genetic variants in conventionally bred populations of plants and microorganisms. Originally developed at the Carlsberg Research Laboratory to improve barley, the technology identifies desirable genetic characteristics without directly editing an organism's DNA.

The platform is designed to accelerate the discovery and development of traits that can improve crop resilience, agricultural productivity and food quality. Unlike approaches developed for specific crops or microbial species, FIND-IT can be applied across different plant and microorganism populations, enabling Traitomic to work with agricultural seed developers, food manufacturers and industrial biotechnology companies.

According to the company, its platform has delivered 116 traits to 47 customers across 32 organisms. These projects include developing crops with improved robustness and yield potential, enhancing the nutritional and storage characteristics of food products, and improving enzymes and microbial strains used in industrial biotechnology.

Investment to accelerate international expansion

Traitomic plans to use the new capital to expand its international customer base and strengthen its scientific and commercial capabilities. The company also intends to broaden its integrated trait development services, supporting customers from the identification of biological challenges through to the development and delivery of traits suitable for commercial evaluation and use.

Gustav Hambraeus, Chief Executive Officer and Co-founder of Traitomic, said the funding would enable the company to strengthen customer partnerships and expand its approach to trait development across additional biological applications. Michael Krel, Partner at Sofinnova Partners, said Traitomic's ability to develop commercially relevant traits across different organisms and industries provides a foundation for future growth. The investment reflects growing interest in biotechnology platforms that can accelerate crop improvement while using genetic variation identified through conventional breeding approaches.

Building on Carlsberg's agricultural research

Traitomic originated from research conducted by Carlsberg to improve barley varieties for brewing applications. Its technology has since expanded into broader agricultural and industrial uses, including crop breeding, food ingredients and microbial biotechnology. Carlsberg continues to support the company's development as Traitomic seeks to establish a larger international presence.

The latest financing is expected to help the company expand its commercial activities and develop new applications for its trait discovery technology. For agricultural businesses, Traitomic's approach offers a potential route to identifying useful crop characteristics without relying on gene editing, although the commercial performance and adoption of individual traits will depend on further development and customer validation.